According to these unprecedented clinical outcomes of CD19-directed CAR T-cells in patients with certain refractory B cell malignancies, the FDA approved two anti-CD19 CAR-T cell therapies (tisagenlecleucel and axicabtagene ciloleucel) for the treatment of certain hematological malignancies in 2017. Here, CD19 is linked to hematologic disorder.